Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2010 Jan 20.
Published in final edited form as: Obesity (Silver Spring). 2008 Nov 6;17(1):126–135. doi: 10.1038/oby.2008.489

Functional consequences of the human leptin receptor (LEPR) Q223R transversion

George Stratigopoulos a,*, Charles A LeDuc a,*, Naoki Matsuoka b, Roee Gutman a, Richard Rausch a, Scott A Robertson c, Martin G Myers Jr c, Wendy K Chung a, Streamson C Chua Jr d, Rudolph L Leibel a
PMCID: PMC2808713  NIHMSID: NIHMS167809  PMID: 18997673

Abstract

Perturbations in the functional integrity of the leptin axis are obvious candidates for mediation of altered adiposity. In a large number of genetic association studies in humans, the non-conservative LEPR Q223R allele has been inconsistently associated with adiposity. Subtle, long term effects of such genetic variants can be obscured by effects of the environment and other confounders that render definitive inferences difficult to reach. We directly assessed the biological effects of this variant in 129P3/J mice segregating for the humanized Lepr allele at codon 223. No effects of this allele were detected on body weight, composition, or energy expenditure in animals fed diets of varying fat content over periods as long as 235 days. In vitro, Q223R did not affect leptin signaling as reflected by activation of STAT3. We conclude that Q223R is unlikely to play a significant role in regulation of human adiposity. This approach to vetting of human allelic variation might be more widely employed.

Keywords: genetics, obesity, leptin, mouse models

Introduction

Leptin plays a central role in the control of human body weight as evidenced by the profound effects on adiposity of null alleles for leptin (LEP) (1, 2, 3, 4) or leptin receptor (LEPR) (5). A more difficult question is to what degree alleles of these genes - with more subtle effects on function or expression - contribute to human adiposity. This question is part of an even larger one: to what extent does allelic variation in genes in the known molecular pathways regulating body weight contribute in additive or epistatic ways to human adiposity?

In mice, haploinsufficiency for Lep or Lepr increases adiposity; and these effects are additive (6). In humans, comparable effects have been described for LEP (7). Genes in the signaling pathways engaged by leptin and other peripheral (insulin, ghrelin, peptide YY) and central (melanocortin 4 receptor, neuropeptide Y, pro-opiomelanocortin, carboxypeptidase E) molecules have been examined by linkage and association studies for contributions to human adiposity. For example, the neuropeptide Y Leu7Pro polymorphism has been associated with higher BMI in premenopausal women (8) and young Dutch males (9). The ghrelin Leu72Met variant is associated with the age of onset of obesity (10). Positive associations with BMI have also been found with common variants of pro-opiomelanocortin and the melanocortin 4 receptor (11, 12, 13). For LEP, associations of the G19A and Gln25Gln (CAA to CAG) polymorphisms with increased body weight have been reported (14, 15). Three missense variants Q223R, K109R, K656N in LEPR with allele frequencies > 5% have been described, and their associations with adiposity examined (16, 17) (see below).

LEPR is a member of the class I cytokine receptor family with six alternative transcripts. In the mouse, the longest isoform (Leprb) is predominately expressed in hypothalamic and other CNS neurons that control food intake, energy balance, and neuroendocrine function, while the shorter isoforms are predominately expressed in several peripheral tissues where their physiological roles are not entirely clear (18, 19, 20, 21). Leptin binding to mouse LEPRb (mLEPRb) stimulates the activity of the associated Janus kinase 2 (JAK2), which initiates intracellular signaling by phosphorylating three sites on the intracellular domain of mLEPRb leading to transcriptional regulation of neuropeptides and other molecules that exert effects on energy homeostasis (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33). All six LEPR isoforms share the same extracellular domain consisting of two cytokine receptor homology (CRH) domains, CRH1 and CRH2, separated by an immunoglobulin (Ig)-like domain and followed by three fibronectin type III (F3) domains (Fig. 1). CRH2 is sufficient for leptin binding and activation of LEPR (34, 35). The CRH1 domain is less conserved, and does not seem to participate in leptin binding or receptor activation (36).

Figure 1. Extracellular domain of the leptin receptor.

Figure 1

A. Subdomains and locations of common polymorphisms of LEPR. B. Generation of mice with the “humanized” leptin receptor. 223Q to 223R substitution (Q223R) in mouse exon 4. Restriction sites used for genotyping are indicated. C. Expression levels in the hypothalamus of the 3 genotypes at amino acid 223 of Leprb. Expression data were normalized to β-actin (N=3) (Abbreviations: CRH- Cytokine Receptor Homology subdomain, CK- Cytokine Receptor subdomain, F3-Fibronectin type III subdomain, Ig-Immunoglobulin).

The K109R polymorphism of LEPR causes a conservative change in the membrane-distal part of the LEPR extracellular domain (Fig. 1). No apparent effect of K109R on BMI has been reported (16, 37, 38, 39, 40, 41, 42). K656N, a non-conservative change present in the membrane-proximal part of the LEPR extracellular domain, shows no association with adiposity (16, 37, 38, 39, 40, 41, 43). The Q223R non-conservative change is located in the CRH1 domain (Fig. 1). A number of studies have reported associations of this variant with increased body weight and fat mass, while others failed to demonstrate association (summarized in Table 1).

Table 1. Association studies of LEPR Q223R with human adiposity.

Author Ethnicity/Subject type Sample Control Association Allele frequency Predisposing Allele Dosage
Positive association studies
Thompson et al, 1997(42) Pima Indians 10 obese (Body fat=40±5%) 10 lean (Body fat=23 ± 5%) Obesity R-0.75 R Hom
Chagnon et al, 2000(49) Caucasian 99 families:522 subjects 4U increase of BMI, 5% increase in %fat R-0.43 R Het/Hom
Yiannakouris et al, 2001(40) Caucasian, 120 17y male & female 2.7U increase of BMI, 4.6% increase in %fat (overweight/obese) R-0.32 R Hom
Quinton et al, 2001(50) Caucasian, 220 Postmen. women 2U increase of BMI, 11% increase in fat mass R-0.6 R
Mattevi et al, 2002(8) Brazilian men & women of European descent 123 overweight & 30 obese (BMI>30) 153 lean (BMI<25) 2.8 U increase of BMI R-0.45 R Het/Hom
Guizar-Mendoza et al, 2005(51) Mexican male &female Adolescent 55 obese (BMI=31.1 ± 3.6) 48 lean (BMI=20.7 ± 3.1) 11% increase in %fat R-0.6 R Het/Hom
Fairbrother et al, 2007(52) Caucasian postmenopausal women 4% increase in fat mass R-0.45 R Het/Hom Hom
Negative association studies

Echwald et al, 1997(39) Danish adolescent males 156 obese (BMI≥31) 205 lean (BMI=21.5 ± 2.2) None with BMI
Gotoda et al, 1997(43) British white men 190 obese males (BMI>28) 132 lean males (BMI<22) None with BMI R-0.43
Matsuoka et al, 1997(41) Japanese male & female 47 obese (BMI=35 ± 6.5) 68 lean (BMI=21.6 ± 2.2) None with BMI R-0.85
Silver et al, 1997(37) Caucasian 175 obese (BMI=6.75 ± 9.6) 107 lean (BMI=21 ± 1.4) None with BMI
Chagnon et al, 1999(53) QFS/169 families/314-325 sib.pairs 114 obese (BMI≥27) 167 lean (BMI<27) None with BMI R-0.51
De Silva et al, 1999(54) Nauruan males 232 obese (BMI=37) None with BMI R-0.89
Chanon et al, 2000(49) African-American 115 families:319 subjects None with BMI, % fat R-0.51
Stefan et al, 2002(55) Pima Indians 268 with low subcut. fat 184 with high sub. fat None with abd., sub. fat R-0.33
Ogawa et al, 2004(56) Japanese middle-aged men and women 175 obese (BMI=6.75 ± 9.6) 107 lean (BMI=21 ± 1.4) None with BMI R-0.85
Van der Vleuten et al, 2006(57) FCH patients, diverse 158 FCH patients (BMI=27.3) 479 relatives and spouses (BMI=24.3, 26.4 resp)) None with BMI, waist circumference R-0.4
Wang et al, 2006(58) Taiwanese male & female Aborigines 226 obese (BMI≥27) 33 extreme (BMI≥35) 182 lean (BMI<25) None with BMI R-0.1
Mergen et al, 2006(59) Turkish male & female 262 obese (BMI≥30) 138 lean (BMI≤25) None with BMI R-0.38

The aim of this study was to examine the functional consequences of Q223R by 1) assessing the effects of a humanized allele on body composition in the mouse; and 2) measuring the functional activity of these Lepr alleles in cultured cells. Mice segregating for Lepr Q223R were generated, and gene dosage effects on adiposity and energy homeostasis were quantified. No effects of this allele were apparent either in vivo or in vitro; relevant caveats are discussed below. We propose that this approach will be useful in vetting the biological relevance of non-synonymous variants in genes mediating putative effects on quantitative traits such as adiposity.

Methods

Humanized Lepr variant Q223R

A targeting construct was designed to use homologous recombination in embryonic stem (ES) cells to replace coding exon 4 of the mouse Lepr gene with a segment that was identical except for codon 223. The targeting construct contained a ∼6Kb fragment (extending from a SwaI site to a PmeI site) that contains coding exon 4. The codon substitution was accomplished by oligonucleotide-directed mutagenesis coupled with PCR. Two overlapping fragments were generated by PCR that encompassed coding exon 4 and flanking sequences. The codon sequence alteration was designed to introduce a novel PvuI site and a novel TaqI site for diagnostic restriction digestions to identify the wild type and novel alleles. The two overlapping fragments were digested with PvuI, ligated, and reamplified to generate one contiguous fragment containing the codon sequence alteration. This fragment was digested with Acc65I and EcoRV and used to replace a similar restriction fragment in the targeting construct. A floxed Pgk-neo cassette was inserted into the EcoRV site that is downstream of coding exon 4. All amplified segments were sequenced to eliminate clones with PCR-related sequence alterations (Fig. 1B). The construct was used for targeting 129P3/J ES cells. Three G418 resistant clones were identified to have homologous recombination at the PGK-neo cassette by PCR. However, only two independent clones were verified to contain the desired codon alteration. Mice carrying the humanized Lepr 223R (equivalent to 222R in the mouse; for simplicity, it will be referred to as 223R) allele were generated by injecting the ES clone into C57BL/6J blastocysts. The floxed Pgk-neo cassette was excised by mating to deleter protamine Cre 129 mice to prevent inadvertent effects due to interference from the Pgk-neo cassette. Mice carrying the neo-less allele were identified by PCR using primers flanking the Pgk-neo cassette insertion point.

The founder progeny (potentially capable of producing either 129 or B6 gametes) were crossed to 129 mice and the DNA of F1 progeny interrogated for the targeted Lepr allele. F1 animals segregating for the targeted Lepr allele (therefore 129 throughout) were intercrossed to generate the animals whose phenotypes are described below.

Husbandry

All mice were housed in groups of 3-4 per cage under a 12:12 hour light-dark cycle in a barrier facility at 21°C. A total of 13 223R/R, 35 223Q/R, 18 223Q/Q male and 23 223R/R, 28 223Q/R, 16 223Q/Q female mice were fed a low fat (LF) diet (9% of calories as fat; Purina Picolab No. 5058 chow, Granville Milling, Creedmoor, NC). In addition, 12 223R/R, 23 223Q/R, 16 223Q/Q male and 12 223R/R, 16 223Q/R, 11 223Q/Q female mice were fed a low fat (LF) (Purina Picolab No. 5058 chow, Granville Milling, Creedmoor, NC) or a high fat (HF) (65% of calories as fat; Cat. No D12492; Open Source Diets™, USA) diet starting at four weeks of age. Mice fed the LF diet from four weeks of age were switched to the HF diet at 121 days of age. All mice had ad libitum access to food and water throughout these studies.

Body mass and composition measurement

Mice were weighed weekly on an electronic scale starting on postnatal day 14. Immediately after weighing, body composition was determined by TD-NMR using a Minispec Analyst AD lean fat analyzer (Bruker Optics, Silberstreifen Germany). The TD-NMR was calibrated using mouse carcasses that ranged from 5 to 70 grams in mass.

Calorimetry and energy intake

150-day old male mice (four 223Q/Q and four 223R/R) were individually caged in a LabMaster-CaloSys-Calorimetry System (TSE Systems, USA) and trained to use the water dispenser. Mice were weighed before being placed in their cages. Indirect calorimetry was performed for ∼96h while the mice had free access to the LF diet. O2 and CO2 measurements were taken every ∼14 minutes during the entire period, and VO2 and VCO2 values were expressed in ml/kg/hr. Mice were taken out of the calorimeter and fed the HF diet ad libitum for 72h. They were then returned to the calorimeter cages with ad lib access to the HF diet and studied for ∼96h as before. Data from only the last 72h on the HF and LF diets were analyzed, as the mice were allowed to acclimate during the first ∼24h. Energy intake was calculated by multiplying cumulative food intake for a 24 hour period by the metabolizable energy present in the HF (5.24 Kcal/g) and LF (3.56 Kcal/g) diets.

Real time PCR

Total RNA was extracted from hypothalami of 15 mice of each of the three 223 genotypes and reverse transcribed using random hexamers (Invitrogen SuperScript III; Carlsbab, California). Real time polymerase chain reaction (PCR) was performed in a LightCycler© II (Roche; Pleasanton, CA) using the LightCycler© FastStart DNA Master SYBR Green kit (Roche; Pleasanton, CA) according to the manufacturer's specifications. The following Lepr exonic primers were used:

5′-CCTCTGCCCCCACTGAAAGACA;

5′-GGGTCACTGTCACTCTGAAGTGCAA.

Lepr expression levels were normalized with β-actin using the following exonic primers:

5′- CTTTGCAGCTCCTTCGTTGC

5′- TCTGACCCATTCCCACCATC

STAT3 activation assay

Materials

Generation of anti-LEPRb antibody has been described previously (44). Antibody against Tyr705 phosphorylated STAT3 was purchased from Cell Signaling Technology (Boston, MA). Leptin was purchased from NHPP (Los Angeles, California). mLEPRb/pCDNA3 has been described previously (45). The function of the Δ65 truncation in the intracellular domain of mLEPRb has been described and LEPRbΔ65/pCDNA3 is the non-chimeric variant which was used previously (46). mLEPRb/pCDNA3 was used as a template for mutagenesis. mLEPRbR223/pCDNA3 was constructed using a two-stage PCR method.

First, the 5′ flanking primer

(5′-CGACTCACTATAGGGAGACCCAAGCTTG),

and the antisense mutagenesis primer

(5′- GACATCAGAGGTGACCGAAAACTCACACC),

were used to amplify the upstream fragment.

The 3′ flanking primer

(5′-GACATCGATCACGTATAATTCAGCATAGCGGT),

and the 5′ mutagenesis primer

(5′-GGTGTGAGTTTTCGGTCACCTCTGATGTC)

were used to amplify the downstream fragment. These PCR products combined and used as template for a second round of PCR using the flanking primers listed above. This PCR product was then inserted into mLEPRb/pCDNA3 using HindIII and XhoI restriction sites. The presence of the desired mutation and the absence of adventitious mutations was confirmed by DNA sequencing.

Cell Lines and Transfection

HEK 293 cells were maintained in a humidified incubator at 37°C with 5% CO2. Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, penicillin and streptomycin was used as growth medium. The appropriate LEPRb and luciferase reporter plasmids were transiently transfected into 293 cells in 12-well plates using Lipofectamine (Invitrogen). 500 ng LEPRb plasmid, 50 ng GAS-Luc (encodes STAT3-responsive gamma interferon-activated sequence driven luciferase), and 50 ng pRL-TK (encodes Renilla luciferase) was transfected per well.

Immunoblotting

Following transfection, cells were switched to serum-free medium and stimulated for 6 hours with various doses of leptin. Cells were harvested in lysis buffer (20 mM Tris pH 7.4, 150 mM NaCl, 1% Nonidet P-40) and insoluble material was cleared by centrifugation. Lysate was denatured in 4× Laemmli buffer and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE gels were transferred to nitrocellulose membranes in Towbin buffer containing 0.02% SDS and 20% methanol. Membranes were blocked for one hour in buffer containing 20 mM Tris (pH 7.4), 150 mM NaCl, and 0.01% Tween 20 (wash buffer) supplemented with 3% bovine serum albumin (block buffer). Membranes were incubated with primary antibody for two hours at room temperature. Membranes were washed three times and incubated with a horseradish peroxidase conjugated secondary antibody for one hour. Membranes were then washed three times, treated with luminescence reagent (Lumi-Light, Roche) and exposed to film.

Luciferase Assays

Following transfection, cells were switched to serum-free medium and stimulated for 6 hours with various doses of leptin. Cells were lysed and assayed with the Stop-n-Glo dual luciferase reporter kit (Promega, USA) according to the kit's instructions; GAS-Luc firefly luciferase activity was normalized for transfection efficiency with Renilla luciferase from the constitutive pRL-TK plasmid.

Statistical analysis

Changes in body composition over time of mice fed LF ot HF diet up to days 120 or 190 were assessed using areas under the curves of body mass, lean mass and fat mass over time for each mouse. One way ANOVA (StatView 5.0; SAS Institute) was used, grouping by sex, genotype, and diet. Effects of the low and high fat diet on energy intake and expenditure, RQ and VO2 were assessed by t-testing the arithmetic mean of the calorimetry readings over 72h. Levels of statistical significance were set at Palpha<0.05.

Ethical use of animals

We certify that all applicable institutional and governmental regulations concerning the ethical use of animals were followed during this research. All protocols were approved by the Columbia University Institutional Animal Care and Use Committee and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Results

Body weight and composition

Exon 4 of mouse Lepr is 76% identical at the DNA level and 70% identical at the amino acid level to the human LEPR. The substitution of the mouse wild type glutamine residue (QCAG) with arginine (RCGA) did not affect Lepr expression in the hypothalamus of mice heterozygous and homozygous for RCGA (Fig. 1C). Genotype did not affect body mass in homozygous (Q/Q, R/R) and heretozygous (Q/R) male or female mice from 14 to day 21 of age (Fig. 2A). Mice of all three genotypes were then fed the HF or the LF diet until 120 days of age. From 14-120 days of age, there were effects of diet composition and sex - but not genotype - on changes in weight, lean and fat mass. (Fig. 2; Table 2). Likewise, responses to the change to a HF diet at 120 days were unaffected by genotype at Lepr 223 (Fig. 3; Table 2).

Figure 2. Body composition of mice fed the HF or LF diet by 223 genotype.

Figure 2

Time course of (A) body weight, (B) lean mass and (C) fat mass of male and female mice by genotype (at Lepr codon 223) fed the LF or HF diet. Body weight, lean and fat mass measurements of mice fed the HF diet were made every week from14 to 130 days of age; an additional measurement was made at 190 days of age. For mice fed the LF diet, these measurements were made every week from 14 to 120 days of age. At day 121, their diet was switched to HF. Each data point is the arithmetic mean of all animals. Error bars represent standard error of the mean. For numbers of animals in each study, see Methods/Husbandry.

Table 2. Statistical analyses of body mass and composition measurements.

ANOVA for body mass and body composition by genotype at Lepr 223 in mice fed HF or LF diets up to day 190. Area Under the Curve from data points taken every week was calculated for each mouse and grouped by (A) sex, diet and genotype (up to day 190), or (B) sex and diet (up to day 120).

Days 21-190 MALE DIFFERENCE MALE DIFFERENCE FEMALE DIFFERENCE FEMALE DIFFERENCE
A DEPENDENT VARIABLE HF: Q/Q, Q/R, R/R LF: Q/Q, Q/R, R/R HF: Q/Q, Q/R, R/R LF: Q/Q, Q/R, R/R
BODY WEIGHT F=0.69, df=2,48, p =0.52 - F=0.42, df=2,63, p =0.66 - F=1.61, df=2,36, p = 0.24 - F=0.94, df=2,64, p = 0.41 -
FAT MASS F=1.92, df=2,48, p =0.19 - F=0.33, df=2,63, p =0.71 - F=2.49, df=2,36, p = 0.13 - F=0.31, df=2,64, p = 0.73 -
LEAN MASS F=1.81, df=2,48, p =0.21 - F=0.09, df=2,63, p =0.90 - F=0.03, df=2,36, p = 0.97 - F=2.66, df=2,64, p = 0.10 -
% FAT F=2.47, df=2,48, p =0.13 - F=0.37, df=2,63, p =0.69 - F=2.06, df=2,36, p = 0.17 - F=0.24, df=2,64, p = 0.78 -
Days 21-120

B DEPENDENT VARIABLE HF, LF HF versus LF HF, LF HF versus LF
BODY WEIGHT F=6.40, df=1,115, p =0.07 - F=8.10, df=1,104, p =0.06 -
FAT MASS F=17.61, df=1,115, p =0.0002 +50% F=49.27, df=1,104, p <0.0001 +54%
LEAN MASS F=185.51, df=1,115, p <0.0001 -27% F=116.56, df=1,104, p <0.0001 -27%
% FAT F=17.35, df=1,115, p =0.0003 +30% F=55.65, df=1,104, p <0.001 +50%

Figure 3. Body weight and composition by Lepr 223 genotype of mice swiched to the HF diet at 121 days.

Figure 3

Time course of (A) body weight, and (B) fat mass of male and female mice fed a HF diet for 13 weeks. Week 1 begins at day 121 of age, when mice were switched to the HF diet. Each data point represents a mean of all animals. Error bars represent standard error of the mean. Data analyzed by ANOVA. For numbers of animals in each study, see Methods/Husbandry.

Calorimetry

Indirect calorimetry on Q/Q and R/R mice fed either the LF or HF diet showed, as expected, that mice on the LF diet had a higher RQ than mice on the HF diet; but this difference was unaffected by genotype at Lepr (Fig. 4C). During these calorimetry studies, mice of neither genotype gained weight after 3 days on the HF or LF diet (Fig. 4A), and had the same energy intake (Fig. 4B) and energy expenditure (Fig. 4E) per day while being fed the HF or LF diet. A time course of VO2 per hour per body mass2/3 indicated that the 24h energy expenditure and diurnal patterns of energy expenditure were indistinguishable between Q/Q and R/R mice fed the HF or LF diets (Fig. 4D).

Figure 4. Metabolic studies of mice fed the HF or LF diet.

Figure 4

Indirect calorimetry performed on mice homozygous for the 223Q or 223R Lepr alleles fed the LF or HF diets. Means and standard deviation of (A) total body mass, (B) energy intake calculated from food intake, (C) respiratory quotient (RQ), (D) time course of oxygen utilization per hour over body mass raised to the 2/3 power (dark background represents hours with lights out) and (E) energy expenditure. Measurements were taken every ∼14 min over a period of 72h. Columns and error bars represent means of respective readings and standard deviation, respectively. For numbers in each study, see Methods/Calorimetry.

In vitro signaling effects of codon 223 genotypes

To investigate a possible alteration in signaling capacity between the 223Q and 223R Lepr alleles, we transfected plasmids encoding, STAT3-signaling defective LeprΔ65C, native Leprb223Q or humanized Leprb223R into 293 cells for the analysis of downstream signaling following treatment with various doses of leptin. The analysis of STAT3 activation by the detection of Tyr705 phosphorylation on endogenous STAT3 by immunoblotting revealed no differences in the extent of phosphorylation of STAT3 by Leprb223Q or Leprb223R (Fig. 5B). Similarly, when Leprb223Q or Leprb223R -mediated STAT3 transcriptional activation was assayed in 293 cells co-transfected with the STAT3-responsive GAS-luciferase reporter plasmid, no differences in leptin-dependent luciferase stimulation were detected between the two Leprb alleles over a range of leptin concentrations (Student's t-test, p>0.05) (Fig. 5A).

Figure 5. In vitro assessment of leptin receptor activity.

Figure 5

Activation of STAT3 in response to leptin stimulation. HEK 293 cells were transfected with the LeprΔ65C (truncated Lepr), LeprbQ223 (native mouse Lepr) and LeprbR223 (“humanized” Lepr) plasmids, as well as the STAT3-responsive GAS-luciferase and control pRL-TK plasmids. Following transfection, cells were made quiescent, then treated with leptin for six hours before lysis. Leptin doses were 0, 20 ng/ml, 200 ng/ml, and 2 mg/ml. Lysates were either subjected to (A) dual luciferase analysis or (B) resolved by SDS-PAGE before transferring to nitrocellulose and immunoblot with the indicated antibody. Bars represent the means of triplicate determinations plus or minus the standard deviation.

Discussion

The Q allele of LEPR is conserved in species from monotremes to humans (Ensemble; Genomic Sequence Alignment). The Q allele is also present in all mouse substrain sequences available at NCBI (http://www.ncbi.nlm.nih.gov/SNP/MouseSNP.cgi). A number of studies have explored the hypothesis that the common, non-conservative variant, LEPR Q223R, predisposes to increased adiposity in humans. Interest in LEPR in this regard derives from its central role in energy homeostasis and the high frequency of this allele in most populations. The results, as noted, have been mixed, and two meta-analyses (17, 47) have concluded that LEPR Q223R is not associated with relative adiposity or obesity. We used the mouse to attempt to make a more definitive finding regarding the biological significance of these alleles of LEPR.

129P3/J mice were transgenically engineered to segregate for the human alleles of LEPR at codon 223. Weight and body composition were assessed in male and female mice fed low and high fat diets over 235 days. Mice were also studied by indirect calorimetry. No effect of the Lepr Q223R genotype was observed for any of the metabolic or body weight/composition phenotypes. Possible reasons for our failure to detect any functional consequence of amino acid substitution at this locus include: 1. Use of Lepr DNA sequence from a mouse strain with unique characteristics rendering the molecule insensitive to the allelic variant; 2. A corollary possibility related to interactions between the mouse Lepr sequence and the “background” genome of the mice examined in this study; 3. The presence of critical differences between mouse and human amino acid sequences in LEPR limiting the impact of the Q223R on a relevant signaling pathway. With regard to #1, there are no coding or intronic splice site sequence differences in Lepr among mouse strains examined to date (NCBI; http://www.ncbi.nlm.nih.gov/SNP/MouseSNP.cgi; database includes sequence from 125 mouse strains). Point #2 is addressed in the penultimate paragraph of the manuscript, just below. With regard to #3, the mouse LEPRb is ∼75% identical at the amino acid level to the human protein (mLEPRb NCBI Accession No CAA71342; Human LEPRb NCBI Accession No NP_002294). In particular, mLEPRb residues associated with JAK2 (human residues 893-898) (62), STAT3 (human residues 1142-1145) (63), SOCS3 (human residue 1142; 27), STAT5 (human residues 1079-1082) (23, 64), SHP-2 (human residues 987-990 including Tyr 987 involved in the generation of mLEPRb autoinhibitory signals) (27, 65) activities are conserved between mouse and human proteins. Similarly, the extracellular domain responsible for leptin binding (mouse residues 323-640) is 85% identical between mouse and human LEPR (34). Specifically, residues within sites I-III modelled to bind leptin are conserved in both mouse and human (36, 66).

The LEPR Q223R substitution is located in the loop connecting the cytokine receptor (CK) and the fibronectin type III (F3) domains of CRH1 (Fig. 1A). Residues in the Ig-like (36), CRH2 (35), and membrane-proximal F3 (48) domains have been implicated in LEPR function. No role has yet been assigned to CRH1 since it is not necessary for leptin binding or LEPR activity (36). CRH1 and CRH2 are 23% identical at the amino acid level. Despite the conservation of critical CRH2 residues in CRH1, the Q223R polymorphism lies in a region unique to CRH1 (Fig. 6), that is not conserved in a number of related cytokine receptors (34). In contrast, the mutation that underlies the leptin insensitivity of fatty rats (Q269P) lies within an important structural subdomain of CRH1, and the Q269P substitution presumably destabilizes the structure of CRH1 and thus the entire LEPR molecule (34, 67, 68). Whatever the functional role (if any) of the LEPR Q223R polymorphism may be, it does not appear to affect leptin signaling as reflected by in vitro activation of STAT3, or the body composition/metabolic performance of mice studied over relatively long periods of time. We conclude from the present analysis that LEPR Q223R is unlikely to play a significant role in risk of human obesity.

Figure 6. Comparison of CRH1 and CRH2.

Figure 6

Alignment of human CRH1 and CRH2 using the Clustal V method. Although the two subdomains show weak identity, key residues are conserved.

The previous association detected in the human association studies may be due to another polymorphism in linkage disequilibrium with LEPR Q223R, or could simply be a spurious finding. There is an important caveat to our conclusions regarding the likely absence of functional consequences of the Q223R alleles of LEPR. We examined the effects of these alleles in a single mouse strain (129P3/J). It is well known that the phenotypic “penetrance” of spontaneous and engineered mutations varies widely depending upon the strain(s) in which the mutation is segregated. The striking differences in diabetes-related phenotypes of Leprdb mutations on the C57BLKS/J and C57BL/6J backgrounds (60) is a relevant example. This sort of effect may also account for apparent racial differences in the phenotypic consequences of genetic variation in humans (eg. TCF7L2) (61). Clearly, studies of the sort described here must be interpreted in the context of such considerations. In this instance, given the discordant results in human studies, our in vivo results in 129 mice, and our in vitro analysis of signaling by the Q223R alleles, we conclude that Q223R allelic variation in LEPR plays a small role (if any) in human adiposity.

The approach used here was designed to provide a prototype for biological assessment of potentially small effects of allelic variants in candidate genes for complex convergent phenotypes such as human obesity. This approach can be used to examine alleles of several genes at one time, to recapitulate implicated haplotypes without confounding due to other genetic variation, or variable environments.

Acknowledgments

This work was supported by RO1 DK52431, R01 DK57631 and an ADA mentored fellowship award. Work was also supported by the New York Obesity Research Center (Grant # 5P30 DK26687-27) and predoctoral training awards from the ADA and AHA.

References

  • 1.Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387:903–8. doi: 10.1038/43185. [DOI] [PubMed] [Google Scholar]
  • 2.Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110:1093–103. doi: 10.1172/JCI15693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gibson WT, Farooqi IS, Moreau M, et al. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab. 2004;89:4821–6. doi: 10.1210/jc.2004-0376. [DOI] [PubMed] [Google Scholar]
  • 4.Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998;18:213–5. doi: 10.1038/ng0398-213. [DOI] [PubMed] [Google Scholar]
  • 5.Clément K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392:398–401. doi: 10.1038/32911. [DOI] [PubMed] [Google Scholar]
  • 6.Chung WK, Belfi K, Chua M, Wiley J, Mackintosh R, Nicolson M, Boozer CN, Leibel RL. Heterozygosity for Lep(ob) or Lepr(db) affects body composition and leptin homeostasis in adult mice. Am J Physiol. 1998;274:R985–90. doi: 10.1152/ajpregu.1998.274.4.R985. [DOI] [PubMed] [Google Scholar]
  • 7.Farooqi IS, Keogh JM, Kamath S, et al. Partial leptin deficiency and human adiposity. Nature. 2001;414:34–5. doi: 10.1038/35102112. [DOI] [PubMed] [Google Scholar]
  • 8.Mattevi VS, Zembrzuski VM, Hutz MH. Association analysis of genes involved in the leptin-signaling pathway with obesity in Brazil. Int J Obes Relat Metab Disord. 2002;26:1179–85. doi: 10.1038/sj.ijo.0802067. [DOI] [PubMed] [Google Scholar]
  • 9.van Rossum CT, Pijl H, Adan RA, Hoebee B, Seidell JC. Polymorphisms in the NPY and AGRP genes and body fatness in Dutch adults. Int J Obes (Lond) 2006;30:1522–8. doi: 10.1038/sj.ijo.0803314. [DOI] [PubMed] [Google Scholar]
  • 10.Miraglia del Giudice E, Santoro N, Cirillo G, et al. Molecular screening of the ghrelin gene in Italian obese children: the Leu72Met variant is associated with an earlier onset of obesity. Int J Obes Relat Metab Disord. 2004;28:447–50. doi: 10.1038/sj.ijo.0802572. [DOI] [PubMed] [Google Scholar]
  • 11.Young EH, Wareham NJ, Farooqi S, et al. The V103I polymorphism of the MC4R gene and obesity: population based studies and meta-analysis of 29 563 individuals. Int J Obes (Lond) 2007;31:1437–41. doi: 10.1038/sj.ijo.0803609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Chen Y, Snieder H, Wang X, et al. Proopiomelanocortin gene variants are associated with serum leptin and body fat in a normal female population. Eur J Hum Genet. 2005;13:772–80. doi: 10.1038/sj.ejhg.5201407. [DOI] [PubMed] [Google Scholar]
  • 13.Baker M, Gaukrodger N, Mayosi BM, et al. Association between common polymorphisms of the proopiomelanocortin gene and body fat distribution: a family study. Diabetes. 2005;54:2492–6. doi: 10.2337/diabetes.54.8.2492. [DOI] [PubMed] [Google Scholar]
  • 14.Hager, Clement K, Francke S et al. A polymorphism in the 5′ untranslated region of the human ob gene is associated with low leptin levels. Int J Obes. 1998;22:200–205. doi: 10.1038/sj.ijo.0800567. [DOI] [PubMed] [Google Scholar]
  • 15.Ohshiro Y, Ueda K, Nishi M, et al. A polymorphic marker in the leptin gene associated with Japanese morbid obesity. J Mol Med. 2000;78:516–520. doi: 10.1007/s001090000143. [DOI] [PubMed] [Google Scholar]
  • 16.Chung WK, Power-Kehoe L, Chua M, et al. Exonic and intronic sequence variation in the human leptin receptor gene (LEPR) Diabetes. 1997;46:1509–11. doi: 10.2337/diab.46.9.1509. [DOI] [PubMed] [Google Scholar]
  • 17.Paracchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: a HuGE review. Am J Epidemiol. 2005;162:101–14. doi: 10.1093/aje/kwi174. [DOI] [PubMed] [Google Scholar]
  • 18.Bjørbæk C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res. 2004;59:305–31. doi: 10.1210/rp.59.1.305. [DOI] [PubMed] [Google Scholar]
  • 19.de Luca C, Kowalski TJ, Zhang Y, et al. Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes. J Clin Invest. 2005;115:3484–93. doi: 10.1172/JCI24059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kowalski TJ, Liu SM, Leibel RL, Chua SC., Jr Transgenic complementation of leptin-receptor deficiency. I. Rescue of the obesity/diabetes phenotype of LEPR-null mice expressing a LEPR-B transgene. Diabetes. 2001;50:425–35. doi: 10.2337/diabetes.50.2.425. [DOI] [PubMed] [Google Scholar]
  • 21.Chua SC, Jr, Liu SM, Li Q, et al. Transgenic complementation of leptin receptor deficiency. II. Increased leptin receptor transgene dose effects on obesity/diabetes and fertility/lactation in lepr-db/db mice. Am J Physiol Endocrinol Metab. 2004;286:E384–92. doi: 10.1152/ajpendo.00349.2003. [DOI] [PubMed] [Google Scholar]
  • 22.Bates SH, Stearns WH, Schubert M, et al. STAT3 signaling is required for leptin regulation of energy balance but not reproduction. Nature. 2003;421:856–859. doi: 10.1038/nature01388. [DOI] [PubMed] [Google Scholar]
  • 23.Gong Y, Ishida-Takahashi R, Villanueva EC, Fingar DC, Münzberg H, Myers MG., Jr The long form of the leptin receptor regulates STAT5 and ribosomal protein S6 via alternate mechanisms. J Biol Chem. 2007;282:31019–27. doi: 10.1074/jbc.M702838200. [DOI] [PubMed] [Google Scholar]
  • 24.Baumann H, Morella KK, White DW, et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A. 1996;93:8374–8. doi: 10.1073/pnas.93.16.8374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Banks AS, Davis SM, Bates SH, Myers MG., Jr Activation of downstream signals by the long form of the leptin receptor. J Biol Chem. 2000;275:14563–14572. doi: 10.1074/jbc.275.19.14563. [DOI] [PubMed] [Google Scholar]
  • 26.Bjørbaek C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem. 2001;276:4747–55. doi: 10.1074/jbc.M007439200. [DOI] [PubMed] [Google Scholar]
  • 27.Bjørbaek C, Lavery HJ, Bates SH, et al. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem. 2000;275:40649–57. doi: 10.1074/jbc.M007577200. [DOI] [PubMed] [Google Scholar]
  • 28.Björnholm M, Münzberg H, Leshan RL, et al. Mice lacking inhibitory leptin receptor signals are lean with normal endocrine function. J Clin Invest. 2007;117:1354–60. doi: 10.1172/JCI30688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569–74. doi: 10.1038/nature02440. [DOI] [PubMed] [Google Scholar]
  • 30.Niswender KD, Morton GJ, Stearns WH, et al. Intracellular signalling Key enzyme in leptin-induced anorexia. Nature. 2001;413:794–5. doi: 10.1038/35101657. [DOI] [PubMed] [Google Scholar]
  • 31.Cota D, Proulx K, Smith KA, et al. Hypothalamic mTOR signaling regulates food intake. Science. 2006;312:927–30. doi: 10.1126/science.1124147. [DOI] [PubMed] [Google Scholar]
  • 32.Xu AW, Kaelin CB, Takeda K, Akira S, Schwartz MW, Barsh GS. PI3K integrates the action of insulin and leptin on hypothalamic neurons. J Clin Invest. 2005;115:951–8. doi: 10.1172/JCI24301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Plum L, Ma X, Hampel B, et al. Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity. J Clin Invest. 2006;116:1886–901. doi: 10.1172/JCI27123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Fong TM, Huang RR, Tota MR, et al. Localization of leptin binding domain in the leptin receptor. Mol Pharmacol. 1998;53:234–40. doi: 10.1124/mol.53.2.234. [DOI] [PubMed] [Google Scholar]
  • 35.Iserentant H, Peelman F, Defeau D, Vandekerckhove J, Zabeau L, Tavernier J. Mapping of the interface between leptin and the leptin receptor CRH2 domain. J Cell Sci. 2005;118:2519–27. doi: 10.1242/jcs.02386. [DOI] [PubMed] [Google Scholar]
  • 36.Peelman F, Iserentant H, De Smet AS, Vandekerckhove J, Zabeau L, Tavernier J. Mapping of binding site III in the leptin receptor and modeling of a hexameric leptin.leptin receptor complex. J Biol Chem. 2006;281:15496–504. doi: 10.1074/jbc.M512622200. [DOI] [PubMed] [Google Scholar]
  • 37.Silver K, Walston J, Chung WK, et al. The Gln223Arg and Lys656Asn polymorphisms in the human leptin receptor do not associate with traits related to obesity. Diabetes. 1997;46:1898–900. doi: 10.2337/diab.46.11.1898. [DOI] [PubMed] [Google Scholar]
  • 38.Mammès O, Aubert R, Betoulle D, et al. LEPR gene polymorphisms: associations with overweight, fat mass and response to diet in women. Eur J Clin Invest. 2001;31:398–404. doi: 10.1046/j.1365-2362.2001.00843.x. [DOI] [PubMed] [Google Scholar]
  • 39.Echwald SM, Sørensen TD, Sørensen TI, et al. Amino acid variants in the human leptin receptor: lack of association to juvenile onset obesity. Biochem Biophys Res Commun. 1997;233:248–52. doi: 10.1006/bbrc.1997.6430. [DOI] [PubMed] [Google Scholar]
  • 40.Yiannakouris N, Yannakoulia M, Melistas L, Chan JL, Klimis-Zacas D, Mantzoros CS. The Q223R polymorphism of the leptin receptor gene is significantly associated with obesity and predicts a small percentage of body weight and body composition variability. J Clin Endocrinol Metab. 2001;86:4434–9. doi: 10.1210/jcem.86.9.7842. [DOI] [PubMed] [Google Scholar]
  • 41.Matsuoka N, Ogawa Y, Hosoda K, et al. Human leptin receptor gene in obese Japanese subjects: evidence against either obesity-causing mutations or association of sequence variants with obesity. Diabetologia. 1997;40:1204–10. doi: 10.1007/s001250050808. [DOI] [PubMed] [Google Scholar]
  • 42.Thompson DB, Ravussin E, Bennett PH, Bogardus C. Structure and sequence variation at the human leptin receptor gene in lean and obese Pima Indians. Hum Mol Genet. 1997;6:675–9. doi: 10.1093/hmg/6.5.675. [DOI] [PubMed] [Google Scholar]
  • 43.Gotoda T, Manning BS, Goldstone AP, et al. Leptin receptor gene variation and obesity: lack of association in a white British male population. Hum Mol Genet. 1997;6:869–76. doi: 10.1093/hmg/6.6.869. [DOI] [PubMed] [Google Scholar]
  • 44.Banks AS, Davis SM, Bates SH, Myers MG., Jr Activation of downstream signals by the long form of the leptin receptor. J Biol Chem. 2000;275:14563–14572. doi: 10.1074/jbc.275.19.14563. [DOI] [PubMed] [Google Scholar]
  • 45.Bjørbæk C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem. 1997;272:32686–32695. doi: 10.1074/jbc.272.51.32686. [DOI] [PubMed] [Google Scholar]
  • 46.Kloek C, Haq AK, Dunn SL, Lavery HJ, Banks AS, Myers MG., Jr Regulation of Jak kinases by intracellular leptin receptor sequences. J Biol Chem. 2002;277:41547–41555. doi: 10.1074/jbc.M205148200. [DOI] [PubMed] [Google Scholar]
  • 47.Heo M, Leibel RL, Fontaine KR, et al. A meta-analytic investigation of linkage and association of common leptin receptor (LEPR) polymorphisms with body mass index and waist circumference. Int J Obes Relat Metab Disord. 2002;26:640–6. doi: 10.1038/sj.ijo.0801990. [DOI] [PubMed] [Google Scholar]
  • 48.Zabeau L, Defeau D, Iserentant H, Vandekerckhove J, Peelman F, Tavernier J. Leptin receptor activation depends on critical cysteine residues in its fibronectin type III subdomains. J Biol Chem. 2005;280:22632–40. doi: 10.1074/jbc.M413308200. [DOI] [PubMed] [Google Scholar]
  • 49.Chagnon YC, Wilmore JH, Borecki IB, et al. Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study. J Clin Endocrinol Metab. 2000;85:29–34. doi: 10.1210/jcem.85.1.6263. [DOI] [PubMed] [Google Scholar]
  • 50.Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI. A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet. 2001;108:233–6. doi: 10.1007/s004390100468. [DOI] [PubMed] [Google Scholar]
  • 51.Guizar-Mendoza JM, Amador-Licona N, Flores-Martinez SE, Lopez-Cardona MG, Ahuatzin-Tremary R, Sanchez-Corona J. Association analysis of the Gln223Arg polymorphism in the human leptin receptor gene, and traits related to obesity in Mexican adolescents. J Hum Hypertens. 2005;19:341–6. doi: 10.1038/sj.jhh.1001824. [DOI] [PubMed] [Google Scholar]
  • 52.Fairbrother UL, Tanko LB, Walley AJ, Christiansen C, Froguel P, Blakemore AI. Leptin receptor genotype at Gln223Arg is associated with body composition, BMD, and vertebral fracture in postmenopausal Danish women. J Bone Miner Res. 2007;22:544–50. doi: 10.1359/jbmr.070114. [DOI] [PubMed] [Google Scholar]
  • 53.Chagnon YC, Chung WK, Perusse L, Chagnon M, Leibel RL, Bouchard C. Linkages and associations between the leptin receptor (LEPR) gene and human body composition in the Quebec Family Study. Int J Obes Relat Metab Disord. 1999;23:278–86. doi: 10.1038/sj.ijo.0800809. [DOI] [PubMed] [Google Scholar]
  • 54.de Silva AM, Walder KR, Aitman TJ, et al. Combination of polymorphisms in OB-R and the OB gene associated with insulin resistance in Nauruan males. Int J Obes Relat Metab Disord. 1999;23:816–22. doi: 10.1038/sj.ijo.0800931. [DOI] [PubMed] [Google Scholar]
  • 55.Stefan N, Vozarova B, Del Parigi A, et al. The Gln223Arg polymorphism of the leptin receptor in Pima Indians: influence on energy expenditure, physical activity and lipid metabolism. Int J Obes Relat Metab Disord. 2002;26:1629–32. doi: 10.1038/sj.ijo.0802161. [DOI] [PubMed] [Google Scholar]
  • 56.Ogawa T, Hirose H, Yamamoto Y, et al. Relationships between serum soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile, and leptin receptor gene polymorphisms in the Japanese population. Metabolism. 2004;53:879–85. doi: 10.1016/j.metabol.2004.02.009. [DOI] [PubMed] [Google Scholar]
  • 57.van der Vleuten GM, Kluijtmans LA, Hijmans A, Blom HJ, Stalenhoef AF, de Graaf J. The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia. Int J Obes (Lond) 2006;30:892–8. doi: 10.1038/sj.ijo.0803234. [DOI] [PubMed] [Google Scholar]
  • 58.Wang TN, Huang MC, Chang WT, et al. G-2548A polymorphism of the leptin gene is correlated with extreme obesity in Taiwanese aborigines. Obesity (Silver Spring) 2006;14:183–7. doi: 10.1038/oby.2006.23. [DOI] [PubMed] [Google Scholar]
  • 59.Mergen H, Karaaslan C, Mergen M, Deniz Ozsoy E, Ozata M. LEPR, ADBR3, IRS-1 and 5-HTT genes polymorphisms do not associate with obesity. Endocr J. 2007;54:89–94. doi: 10.1507/endocrj.k06-023. [DOI] [PubMed] [Google Scholar]
  • 60.Coleman DL. The influence of genetic background on the expression of mutations at the diabetes (db) locus in the mouse. VI: Hepatic malic enzyme activity is associated with diabetes severity. Metabolism. 1992;41:1134–6. doi: 10.1016/0026-0495(92)90299-p. [DOI] [PubMed] [Google Scholar]
  • 61.Guo T, Hanson RL, Traurig M, Muller YL, et al. TCF7L2 is not a major susceptibility gene for type 2 diabetes in Pima Indians: analysis of 3,501 individuals. Diabetes. 2007;56:3082–8. doi: 10.2337/db07-0621. [DOI] [PubMed] [Google Scholar]
  • 62.Bahrenberg G, Behrmann I, Barthel A, Hekerman P, Heinrich PC, Joost HG, Becker W. Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and activator of transcription activation by receptor heterodimers. Mol Endocrinol. 2002;16:859–72. doi: 10.1210/mend.16.4.0800. [DOI] [PubMed] [Google Scholar]
  • 63.Haan S, Hemmann U, Hassiepen U, Schaper F, Schneider-Mergener J, Wollmer A, Heinrich PC, Grötzinger J. Characterization and binding specificity of the monomeric STAT3-SH2 domain. J Biol Chem. 1999;274:1342–8. doi: 10.1074/jbc.274.3.1342. [DOI] [PubMed] [Google Scholar]
  • 64.Hekerman P, Zeidler J, Bamberg-Lemper S, Knobelspies H, Lavens D, Tavernier J, Joost HG, Becker W. Pleiotropy of leptin receptor signalling is defined by distinct roles of the intracellular tyrosines. FEBS J. 2005;272:109–19. doi: 10.1111/j.1742-4658.2004.04391.x. [DOI] [PubMed] [Google Scholar]
  • 65.Björnholm M, Münzberg H, Leshan RL, Villanueva EC, Bates SH, Louis GW, Jones JC, Ishida-Takahashi R, Bjørbaek C, Myers MG., Jr Mice lacking inhibitory leptin receptor signals are lean with normal endocrine function. J Clin Invest. 2007;117:1354–60. doi: 10.1172/JCI30688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Peelman F, Van Beneden K, Zabeau L, Iserentant H, Ulrichts P, Defeau D, Verhee A, Catteeuw D, Elewaut D, Tavernier J. Mapping of the leptin binding sites and design of a leptin antagonist. J Biol Chem. 2004;279:41038–46. doi: 10.1074/jbc.M404962200. [DOI] [PubMed] [Google Scholar]
  • 67.Chua SC, Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996;271:994–6. doi: 10.1126/science.271.5251.994. [DOI] [PubMed] [Google Scholar]
  • 68.White DW, Wang DW, Chua SC, Jr, Morgenstern JP, Leibel RL, Baumann H, Tartaglia LA. Constitutive and impaired signaling of leptin receptors containing the Gln --> Pro extracellular domain fatty mutation. Proc Natl Acad Sci U S A. 1997;94:10657–62. doi: 10.1073/pnas.94.20.10657. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES